Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
Rhea-AI Summary
Lilly (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, chief scientific and product officer and president of Lilly Research Laboratories, will join a fireside chat at 1:30 p.m. Eastern time.
A live audio webcast and a 90-day replay will be available on Lilly's investor website under "Webcasts & Presentations".
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LLY
On the day this news was published, LLY declined 1.67%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LLY slipped 0.18% while key peers ABBV, JNJ, AZN, NVS, and NVO also traded lower (-0.91% to -1.72%), but no momentum scanner signals or broad sector theme were flagged.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | UNICEF collaboration | Positive | -0.9% | Six-year $50M UNICEF NCD initiative for 30M children and caregivers. |
| May 12 | Obesity trial data | Positive | +2.6% | Late-phase data on Foundayo and Zepbound maintaining weight loss after switch. |
| May 12 | Community initiative | Positive | +2.4% | 150th anniversary program supporting 500,000 meals and 150 food pantries. |
| May 6 | Capex expansion | Positive | -0.2% | $4.5B Indiana investment and opening of genetic medicine facility. |
| May 5 | Clinical durability data | Positive | +2.2% | Omvoh four-year disease clearance durability in ulcerative colitis. |
Recent news has mostly been positive, with three of five events seeing share gains and two showing mild negative or flat reactions despite constructive headlines.
Over the past few weeks, LLY has reported strong clinical, strategic, and community-focused updates. Positive Omvoh ulcerative colitis data on May 5, major Indiana manufacturing investments on May 6, and obesity drug data on May 12 were followed by mixed price moves. Philanthropic and UNICEF collaborations also featured, indicating an active news cadence. Today’s conference participation fits into this pattern of frequent investor communications rather than a new financial or clinical catalyst.
Market Pulse Summary
This announcement highlights LLY’s plan to engage investors at a major conference via a fireside chat on May 28, 2026, with a webcast and 90-day replay. It follows a series of strong earnings, clinical, and strategic updates in recent weeks, reinforcing ongoing investor outreach rather than introducing new financial metrics. Observers may focus on how management frames growth, R&D priorities, and capital allocation in light of recent results and large-scale investments.
AI-generated analysis. Not financial advice.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-bernsteins-42nd-annual-strategic-decisions-conference-302774752.html
SOURCE Eli Lilly and Company